Capricor Therapeutics (CAPR) Q3 2024 Earnings
CAPR·Reported November 13, 2024·After market close
Capricor Therapeutics reported Q3 2024 revenue of $2.3M, missed analyst consensus of $9.9M by $7.6M. Diluted EPS came in at $-0.38, missed the $-0.36 consensus by $0.02.
Revenue
$2.3Mmissed by $7.6M
Consensus: $9.9MDiluted EPS
$-0.38missed by $0.02
Consensus: $-0.36
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Capricor Therapeutics's Q3 2024 earnings report.
Capricor Therapeutics (CAPR) reported Q3 2024 earnings on November 13, 2024 after market close.
Capricor Therapeutics reported revenue of $2.3M and diluted EPS of $-0.38 for Q3 2024.
Revenue missed the consensus estimate of $9.9M by $7.6M. EPS missed the consensus estimate of $-0.36 by $0.02.
You can read the 10-Q periodic report (0001558370-24-015730) directly on SEC EDGAR. The filing index links above go to sec.gov.